Objective To derive and validate decision trees to categorise rheumatoid arthritis (RA) patients 12 weeks after starting etanercept with or without methotrexate into three groups: patients predicted to achieve low disease activity (LDA) at 1 year; patients predicted not to achieve LDA at 1 year and patients who needed additional time on therapy to be categorised.
Methods Data from RA patients enrolled in the TEMPO trial were analysed. Classification and regression trees were used to develop and validate decision tree models with week 12 and earlier assessments that predicted long-term LDA. LDA, defined as disease activity score in 28 joints (DAS28) ≤3.2 or clinical disease activity index ≤10.0, was measured at 52 or 48 weeks. Demographics, laboratory data and clinical data at baseline and to week 12 were analysed as predictors of response.
Results 39% (67/172) of patients receiving etanercept and 60% (115/193) of patients receiving etanercept plus methotrexate achieved LDA at week 52. For patients receiving etanercept, 53% were predicted to have LDA, 39% were predicted not to have LDA and 8% could not be categorised using DAS28 criteria at week 12. For patients receiving etanercept plus methotrexate, 63% were predicted to have LDA, 25% were predicted not to have LDA and 12% could not be categorised.
Conclusion Most (80–90%) patients in TEMPO initiating etanercept with or without methotrexate could be predicted within 12 weeks of starting therapy as likely to have LDA or not at week 52. However, approximately 10–20% of patients needed additional time on therapy to decide whether to continue treatment.
Statistics from Altmetric.com
Funding This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. and by Wyeth, which was acquired by Pfizer Inc. in October 2009. Data were obtained from Wyeth (Pfizer). JRC receives support from the Agency for Healthcare Research and Quality (R01HS018517) and the NIH (AR053351).
Competing interests JRC has received research grants from Amgen, Genentech, Bristol-Myer-Squibb, Abbott, Centocor and CORRONA; has consulting arrangements/honoraria from Genentech, UCB, Centocor, Amgen and CORRONA. SY, LC and IN-M have no competing interests to disclose. GSP and BB are compensated employees and shareholders of Amgen Inc. BW is a compensated contractor of Amgen Inc. AK has received research grants from Amgen.
Ethics approval This study was conducted with the approval of the multinational participating centres, obtained from local institutional review boards.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.